Last update 01 Nov 2024

TAM/CSF1R/NTRK inhibitor(TransThera Sciences)

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms-
Target
CSF-1R x NTRK x TAM family
Mechanism
CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), TAM family inhibitors(Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesCardiovascular Diseases+ [3]
Active Indication
EndometriosisKidney DiseasesNeoplasms+ [4]
Inactive Indication-
Originator Organization
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
Active Organization
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
Inactive Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with TAM/CSF1R/NTRK inhibitor(TransThera Sciences)
Login to view more data
100 Translational Medicine associated with TAM/CSF1R/NTRK inhibitor(TransThera Sciences)
Login to view more data
100 Patents (Medical) associated with TAM/CSF1R/NTRK inhibitor(TransThera Sciences)
Login to view more data
100 Deals associated with TAM/CSF1R/NTRK inhibitor(TransThera Sciences)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EndometriosisPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
Kidney DiseasesPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
NeoplasmsPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
OsteoporosisPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
PsoriasisPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
Rheumatoid ArthritisPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
Vascular DiseasesPreclinical
CN
TransThera Sciences (Nanjing), Inc.TransThera Sciences (Nanjing), Inc.Startup
03 Mar 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free